Key Events This Week
23 Mar: Stock hits 52-week low at Rs.1.82 amid market downturn
24 Mar: Valuation shifts to fair grade with Strong Sell mojo rating
27 Mar: New 52-week low recorded at Rs.1.81
Weekly Close: Rs.1.80, down 5.76% for the week
23 March 2026: Fresh 52-Week Low Amid Broader Market Weakness
Vivanza Biosciences Ltd’s share price dropped sharply to Rs.1.82 on 23 March 2026, marking a new 52-week low and a 4.71% decline on the day. This fall was more pronounced than the Sensex’s 3.13% drop, reflecting both sectoral and company-specific pressures. The stock traded below all key moving averages, signalling persistent bearish momentum.
The broader market was under significant pressure, with the Sensex closing at 32,377.87, down 1,045.74 points. Vivanza’s underperformance was compounded by concerns over its financial health, including a high Debt to EBITDA ratio of 5.05 times and a negative operating profit CAGR of -4.85% over five years. Despite reporting net sales growth of 1,478.53% for the nine months ended December 2025, profitability remained modest with a PAT of Rs.0.85 crore and a negative ROCE of -0.6%.
24 March 2026: Valuation Downgrade Reflects Heightened Investor Caution
On 24 March, Vivanza Biosciences maintained its price at Rs.1.82, with no change from the previous day. However, the company’s valuation profile shifted notably, moving from an attractive to a fair valuation grade amid ongoing financial challenges. The mojo grade was downgraded to Strong Sell, underscoring deteriorating investor sentiment.
Key valuation metrics painted a challenging picture: a deeply negative P/E ratio of -48.53, negative EV/EBITDA and EV/EBIT multiples at -16.82, and negative returns on capital employed and equity (-0.64% and -6.72%, respectively). These figures contrasted sharply with sector peers, many of whom trade at significantly higher multiples and enjoy positive profitability metrics. The stock’s price-to-book value ratio of 1.58, while above 1, was modest compared to more favourably rated companies.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
27 March 2026: Another 52-Week Low Amid Continued Market Pressures
Vivanza Biosciences’ stock declined further to Rs.1.80 on 27 March 2026, registering a 2.70% drop on the day and setting a fresh 52-week low. This decline occurred despite the stock marginally outperforming its sector, which fell by 2.69%. The Sensex also fell by 2.11% to close at 32,935.19, reflecting ongoing market volatility.
Financially, the company’s long-term challenges persisted, with a five-year operating profit CAGR of -4.85% and a high leverage ratio. However, some recent operational improvements were noted, including net sales of Rs.100.61 crores and a PAT of Rs.0.76 crore for the latest six-month period, though profit trends declined by 7% year-on-year. Technical indicators remained predominantly bearish, with the MACD and Bollinger Bands signalling downward momentum on weekly and monthly charts.
Is Vivanza Biosciences Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Daily Price Performance Compared to Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-23 | Rs.1.82 | -4.71% | 32,377.87 | -3.13% |
| 2026-03-24 | Rs.1.82 | +0.00% | 33,009.57 | +1.95% |
| 2026-03-25 | Rs.1.85 | +1.65% | 33,645.89 | +1.93% |
| 2026-03-27 | Rs.1.80 | -2.70% | 32,935.19 | -2.11% |
Key Takeaways from the Week
Negative Price Momentum: Vivanza Biosciences’ stock declined 5.76% over the week, significantly underperforming the Sensex’s 1.46% fall. The stock’s repeated 52-week lows highlight persistent bearish sentiment and technical weakness.
Financial and Valuation Challenges: The company’s financial metrics remain concerning, with negative profitability ratios, high leverage, and a downgrade to a Strong Sell mojo grade. Valuation multiples such as P/E and EV/EBITDA are deeply negative, reflecting ongoing operational struggles.
Modest Operational Improvements: Despite the negative price trend, recent sales and profit figures showed some improvement, with net sales rising to Rs.100.61 crores and PAT to Rs.0.76 crore in the latest six-month period. However, these gains have yet to translate into sustained positive momentum.
Conclusion
Vivanza Biosciences Ltd’s week was marked by continued downward pressure on its share price, driven by weak financial fundamentals and a challenging market environment. The stock’s 5.76% weekly decline and fresh 52-week lows underscore the difficulties faced by this micro-cap company in the Pharmaceuticals & Biotechnology sector. While some operational metrics showed modest improvement, the overall financial health remains fragile, with negative returns and high leverage weighing on investor confidence. The downgrade to a Strong Sell mojo grade and fair valuation status reflect these concerns. Investors should remain cautious given the persistent bearish technical signals and the company’s underperformance relative to the broader market.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
